(Z)-SU4312 NEW
| Price | $56 | $125 | $190 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-21 |
Product Details
| Product Name: (Z)-SU4312 | CAS No.: 90828-16-3 |
| Purity: 99.84% | Supply Ability: 10g |
| Release date: 2026/04/21 |
Product Introduction
Bioactivity
| Name | (Z)-SU4312 |
| Description | (Z)-SU4312 is a inhibitor of MAO-B and NOS(IC50 value of 0.2 μM, 19.0μM,respectively). |
| Animal Research | MPP(+) -treated neurons and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated zebrafish were used to study neuroprotection by?(Z)-SU4312. NOS activity was assayed in vitro to examine direct interactions between?SU4312?and NOS isoforms[1]. |
| In vitro | (Z)-SU4312 unexpectedly prevented MPP(+) -induced neuronal apoptosis in vitro and decreased MPTP-induced loss of dopaminergic neurons, reduced expression of mRNA for tyrosine hydroxylase and impaired swimming behaviour in zebrafish.?(Z)-SU4312 exhibited non-competitive inhibition of purified neuronal NOS (nNOS) with an IC(50) value of 19.0?μM but showed little or no effects on inducible and endothelial NOS. Molecular docking simulations suggested an interaction between (Z)-SU4312 and the haem group within the active centre of nNOS[1]. |
| In vivo | (Z)-SU4312 was able to selectively inhibit monoamine oxidase-B (MAO-B) activity both in vitro and in vivo, with an IC50 value of 0.2 μM.(Z)-SU43122 provides therapeutic benefits in cellular and animal models of PD, possibly through multiple mechanisms including enhancement of MEF2D through the activation of PI3-K/Akt pathway, maintenance of mitochondrial biogenesis and inhibition of MAO-B activity.?(Z)-SU4312 thus may be an effective drug candidate for the prevention or even modification of the pathological processes of PD[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 30 mg/mL (113.5 mM), Sonication is recommended. |
| Keywords | SU-4312 | SU4312 | SU 4312 | NOS | MAO-B | (Z)-SU-4312 | (Z)SU4312 | (Z) SU4312 |
| Inhibitors Related | Ribociclib | L-NAME hydrochloride | Sorafenib | 1,4-Naphthoquinone | Dexamethasone acetate | Nintedanib esylate | Paeonol | Hydroxylamine hydrochloride | Chloramphenicol | Diallyl disulfide | Lenvatinib | Pazopanib |
| Related Compound Libraries | Mitochondrial Membrane Protein-Targeted Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Parkinson's Disease Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP5Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2026-07-06 | ||
| $30.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-26 | |
| $1520.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY